MedTrace Logo

Opioid, HIV and Immune System

NCT04304768 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this research is to evaluate blood samples from HIV infected and non-HIV infected people opioid and non opioid users to understand how opioid affect the immune responses (body defenses against infection) to the flu vaccine.

Conditions

  • Immune Defect

Interventions

BIOLOGICAL

Fluzone Quadrivalent

0.5 ml prefilled syringe administrated intramuscularly

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Savita Pahwa, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2027-01-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04304768 on ClinicalTrials.gov